The last time I wrote an article on ORIC Pharmaceuticals (NASDAQ:ORIC) it was with respect to a Seeking Alpha article entitled "ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could ...

ORIC Pharmaceuticals has promising early data for ORIC-944 and ORIC-114, targeting prostate and lung cancer, but remains in very early clinical stages. Financially, ORIC is well-capitalized for ...

On Tuesday, H.C. Wainwright research firm maintained a positive outlook on ORIC Pharmaceuticals (NASDAQ:ORIC), reiterating a Buy rating and a $21.00 price target for the company's stock.

In preclinical prostate cancer models, ORIC-944 demonstrated robust inhibition of PRC2, enhanced luminal cell state, and increased androgen receptor (AR) signaling. Analysis of chromatin revealed ...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that ...